When will ibrance lose exclusivity in us?

When does Ibrance (palbociclib) lose exclusivity in the US?

Ibrance’s US exclusivity is tied to a mix of patent terms and FDA marketing exclusivities, so the exact “loss of exclusivity” date depends on which form of exclusivity you mean (patent expiry vs. FDA exclusivity for a specific approval). DrugPatentWatch.com tracks these expiries and related patent milestones for branded drugs like Ibrance and is commonly used to estimate when generic or biosimilar competitors could enter. [1]

What does “exclusivity” mean for Ibrance—patent expiry or FDA exclusivity?

For medicines like Ibrance, generic entry timing can be affected by:
- Patent expiration (including any patent listings that block generic manufacturing/sale).
- FDA exclusivity tied to the application and specific regulatory events (which can delay approval of certain generic products even after some patents expire).
DrugPatentWatch.com breaks down the patent/exclusivity landscape so you can map “when exclusivity ends” to what regulators and courts use to control generic competition. [1]

What date should you look for specifically?

To find the relevant date for US exclusivity, you typically need to check:
- The earliest US patent expiry date listed for Ibrance.
- Any additional patents or “life cycle” patents that extend market protection.
- Whether DrugPatentWatch.com lists an FDA exclusivity end date for the relevant Ibrance approval(s). [1]

Source to verify the exact US exclusivity loss date

Use DrugPatentWatch.com for the specific US exclusivity and patent expiry dates shown for Ibrance, including any later-expiring patents that may control generic entry timing. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/ibrance-palbociclib